原料药DMF编写要点-中英对照

原料药DMF
使用说明：
1、本大纲是为了帮助我公司客户把握DMF的整体内容而准备的，由于DMF内容繁多，从整体上了解内容框架和组成部分，对于理解FDA对DMF的要求和意图非常有必要；
2、根据FDA的要求，凡是本大纲提到的内容，原料药制造商均应该提供。

因此，客户务必依照规定提供尽可能详细的内容。

3、本大纲的内容和相关要求能够确保客户目前的运作达到FDA的cGMP标准，因此，准备DMF的过程，也使客户按照FDA的要求进行整改和提高的过程，这些都为FDA未来的现场检查打下良好基础；
4、凡是本大纲中提到的非技术性具体内容要求，请参照本公司专有的与此大纲配套的相关DFM指导性文件，包括《FDA药物主文件指南》、《关于在药品递交中递交的有关原料药生产的支持文件的指南》、《药物申办中质量管理方面通用技术文件格式与内容要求》；
5、凡是本大纲中提到的技术性具体内容要求，如杂质、稳定性、验证等具体技术要求，请参照本公司专有的FDA相关技术标准文件，包括《原料药认证指南》、《制剂认证指南》、《化学药物稳定性指南》、《化学药物杂质指南》、《化学药物化验与合格参数指南》、《化学药物验证指南》等；
《合成原料药DMF起草大纲》
一、公司和生产场地的基本描述
1、第一类的DMF文件建议由位于美国之外的人提供，以帮助FDA对他们的生产设施进行现场检查。

DMF文件应描述生产场地、设备能力、生产流程图等。

A Type I DMF is recommended for a person outside of the United States to assist FDA in conducting on site inspections of their manufacturing facilities. The DMF should describe the manufacturing site, equipment capabilities, and operational layout.
2、第一类的DMF文件对美国国内设施通常不需要，除非该设施没有登记并定期接受检查。

A Type I DMF is normally not needed to describe domestic facilities, except in special cases, such as when a person is not registered and not routinely inspected.
3、场地的描述应包括面积、实际地址以及表明该场地与最近的城市的距离的地图。

提供该场地的鸟瞰图和平面图。

The description of the site should include acreage, actual site address, and a map showing its location with respect to the nearest city. An aerial photograph and a diagram of the site may be helpful.
4、主要生产和加工区域的平面图对于理解整个生产布局会有帮助。

应当描述主要设备的生产能力、用途和位置。

通常不用描述设备的制造商和型号，除非特别新或独特的设备。

A diagram of major production and processing areas is helpful for understanding the operational layout. Major equipment should be described in terms of capabilities, application, and location. Make and model would not normally be needed unless the equipment is new or unique.
5、公司主要的组成部门结构图，包括总公司和生产场地的关键生产、质量控制、质量保证岗位，A diagram of major corporate organizational elements, with key manufacturing, quality control, and quality assurance positions highlighted, at both the manufacturing site and corporate headquarters, is also helpful.
二、原料药的物理和化学特征
1、特性Properties
相关法规要求对原料药的物理和化学特征做出详细描述。

该要求可以通过提供下述信息来满足：名称（通用名、化学名、编码等）、化学摘要服务(CAS)编码、性状描述（如：外观、颜色、物理状态）、分子式和分子重量、结构式（包括离子状态）、立体化学（找出手性中心、顺式反式异性等）、对映结构体比率（如：外消旋物、规定的异构体、对映异构物和固态形式的混合物）、溶解度概况（水溶性的或非水溶性的）、分配系数、溶液pH值、解离常数、熔点或沸点、折射率、比重。

对于蛋白质原料药，参见：“CRC生物化学和分子生物学手册” “酶学方法”和有关描述蛋白质特性的专论。

The regulations require a full description of the physical and chemical characteristics of the drug substance. This requirement may be satisfied by the submission of information such as the following: name (generic name, chemical name, code number); Chemical Abstracts Service (CAS) number if available; description (e.g., appearance, color, physical state); molecular formula and molecular weight; structural formula (including ionic state if applicable); stereochemistry (identifying chiral centers, cis-trans isomerism, etc.); enantiomer or solid-state form ratios (e.g., for racemates, and for defined admixtures of isomers or enantiomers or solid-state forms); solubility profile (aqueous and nonaqueous as applicable); partition coefficients; solution pH; dissociation constant(s); melting or boiling point; refractive index; specific gravity. For drug substances that are proteins, see the "CRC Handbook of Biochemistry and Molecular Biology," "Methods in Enzymology," and related monographs for how protein properties may be described.
并非所有的递交都要求上述信息，额外的信息也可能需要，特别是随着生产工艺的复杂性的增加。

The items above are not necessary or appropriate for all submissions. Additional information may be required, particularly as the state of the art progresses.
2、结构Structure
对于结构的说明（如：相关数据和其解释）应当基于一个合适的物理和化学检测结果。

这包括以下内容：元素分析；质谱分析(MS)；核磁共振(NMR)；紫外(UV)和红外(IR)光谱学；分子量测定；立体化学和构象分析（如：光学和几何学异构体）；X光分析；降解分析（如：氨基酸排序和分析）；色析图谱；其它检验（如：功能团分析，衍生作用，络合形式等）The elucidation of structure (e.g., the data and its interpretation) should be based on appropriate physical and chemical test results. These may include the following: elemental analysis; mass spectrometry (MS); nuclear magnetic
resonance (NMR), ultraviolet (UV), and infrared (IR) spectroscopy; molecular
weight determination; stereochemistry and configurational or conformational
analysis (e.g., optical and geometric isomers); X-ray analysis; degradative
analysis (e.g., amino acid sequencing and/or analysis); chromatographic
profile; other tests (e.g., functional group analysis, derivatization, complex
formation).
同样，并非所有以上条目都是必须的或适用于所有情况，所列条目也不是完全的（工艺过程更加复杂和新原料药需要时，也许需要做出更多的分析）。

实际数据及其解释的细节应当放在“参考标准”章节（参见II.F.2, 和3）。

Again, not all items are necessary or appropriate in all cases, and the listing should not be considered limiting (i.e., more analysis may be required as the state of the art progresses and the nature of the new drug substance demands). The actual data and the details of its interpretation should be placed in the section for Reference Standard (see II.F.2, and 3.).
三、原料药的稳定性
相关法规要求对原料药的稳定性做全面的描述。

具体要求，参见“关于提交人类用药品和生物制品稳定性文件的指南”。

The regulations require a full description of the stability of the drug substance. See the "Guideline for Submitting Documentation for the Stability of Human Drugs and Biologics" for assistance in fulfilling this requirement.
四、原料药的生产
1、起始材料的控制程序Control procedures for starting materials
应当列出起始原料。

应该提供其承诺的标准和用来判定其特性、质量和纯度的检验方法。

分析检验方法应当简要描述。

起始原料的来源通常无需说明，但有时会要。

Starting materials should be listed. Acceptance specifications and tests defining identity, quality, and purity should be provided. The analytical test methods should be briefly described. The source of the starting material need not be identified, but may be requested.
对起始材料应该进行鉴别和含量测定分析。

在某些情况下，当杂质（如芳香化合物的异构体）被混入原料药时，应提供纯度档案（如包括杂质的定量与定性色谱图）。

通过定期与不定期的核查与验证来评估原料供应商提供的产品质量是稳定的，供应商提供的质量保障声明应该包括相关的规格和结果,并应该注明用于检测的分析方法。

A specific identity test should be performed, as well as an assay, with limits for impurities. In those cases where impurities (e.g., positional isomers of aromatic compounds) could be carried through to the drug substance, a purity profile should be provided (e.g., chromatography with quantitation/identification of impurities). Assurances or statements of quality from the supplier are acceptable for the profile, provided that the manufacturer establishes the reliability of the supplier#39;s analyses through validation, initially and at appropriate intervals. These statements from suppliers should include specifications and results and should indicate the type of method
2、试剂、溶媒和辅料控制Reagents, solvents, and auxiliary materials controls
应列出合成原料、溶媒的内容。

标明以上原料、溶媒的规格和检验方法，并应该提供相关的质量声明。

递交者应当注明具体的检验方法（除非忽略这种检验可被认为是正当的）。

无论是原料供应商还是递交者，进行额外检验时，应该依据该化学成分在合成中的作用进行。

例如，对于用来中和合成反应混合物中多余的酸用得碱时(如氢氧化钠)，通常不需要进行的纯
度检测。

相反，用于关键环节的光学活性的有机酸（如：某种酸的对映体），则需要这样的额外检测。

These chemicals should also be listed. The specifications and test methods for each such material should be stated, and/or a statement of quality provided. The applicant should describe the specific identity test performed (unless omitting such a test has been otherwise justified, e.g., because of hazard). The extent of additional testing performed –whether by the supplier or by the applicant -- should be based on the role of the chemical in the synthesis. For example: a base (e.g., sodium hydroxide) used to neutralize excess acid in a synthetic reaction mixture would not normally require extensive purity testing; in contrast, an optically active organic acid used in a resolution step (e.g., one enantiomer of dibenzoyltartaric acid) would require such additional testing.
3、详细的合成信息
递交者应当提供完整的合成信息，从起始原料到最终成品原料药。

有关描述应当包括整个合成过程的流程图以及每一合成步骤的说明）。

An applicant should provide complete information on the synthesis, from starting material(s) to the bulk new drug substance. The description should contain a diagrammatic flow chart of the whole synthesis and a written statement for each step of the synthesis.
（1）合成流程图Flow chart of the synthesis.
合成的流程图应该包括以下内容The flow chart typically should contain the following:
(1) 反应物和产品的化学结构（如：起始原料、中间体，以及引入到结构中的分子）Chemical structures of reactants (i.e., starting materials and
intermediates, and also molecules incorporated into the structure) and
products;
(2) ) 立体化学结构，如果有立体化学构形
Stereochemical configurations, where applicable;
(3) 中间体（未分离的或已分离的）Intermediates (either in situ or isolated);
(4) 溶媒、催化剂和试剂Solvents, catalysts, and reagents;
反应所产生的产品与副产品混合比率(如：两个或更多异构体)应该显示在流程图上。

重要的副产品和杂质，尤其是那些干扰分析过程或有毒性的，应当被分别表示出来（参见：第II.D.2.c. 和II.F.3.） A ratio or mixture of products (e.g., two or more isomers) produced by a reaction should be shown in the flow chart. Significant side products and impurities, particularly those that interfere with the analytical procedures or are toxic, should be illustrated separately (see sections II.D.2.c. and II.F.3.).
（2）合成描述Description of the synthesis
每一个合成步骤的书面描述以及更详细的最后加工步骤的描述应该包括以下内容The written statement for each step of the synthesis, with greater detail
included toward the final steps of the process, should include the following:
(1) 用于反应的典型设备Typical equipment used for the reaction;
(2) 反应物（本步骤所使用的起始原料或中间体，包括化学名称和数量）Reactants (starting material or intermediate used in the step, with chemical names and amounts);
(3) 溶媒、催化剂和试剂（注明化学名称和数量）Solvents, catalysts, and reagents (chemical names and amounts);
(4) 反应条件（温度，pH值，时间，压力等）Conditions (temperature, pH, time, pressure, etc.);
(5) 反应完成的检测，如果有的话。

Tests for completion of reaction, if employed;
(6) 分离的程序Workup and isolation procedures;
(7) 原料药和中间体的纯化过程，如果有。

Purification procedures for drug substance and for intermediates, if employed;
(8) 收率范围（初品和/或精品的重量和百分比）Yield ranges (crude and/or purified; weight and percent).
应该提供原料药最后合成、分离和提纯的详细信息。

(参见第II.D.2.c部分关于原料药提纯的内容)。

The final step of the synthesis and the isolation of the crude new drug substance, as well as its purification, should be provided in full detail. (See section II.D.2.c below regarding purification of the drug substance.)
除了提供合成的书面描述，还包括经过确认的操作参数范围（参见第II节-E工艺控制）和第IV节[CGMP])以及预期收率，递交者同时要提供实际操作的书面实例（BPR），明确指出它是供审阅官参考。

这个例证不应该仅仅是批生产纪录的拷贝，它应该包括更详细的内容。

Besides providing a written description of the synthesis which includes verified ranges for the operating parameters (refer to section II-E [Process Controls] and section IV [CGMP]) and for the expected yield, the applicant should provide a written example of actual practice, clearly identified as an example for the reviewer's information. This example should not be merely a copy of batch records but should contain more detail.
应该描述所采取的替代措施（如：替代起始原料、反应物、溶媒、条件、催化剂、分析和提纯过程）。

应该提供每一不同合成方法所生产的原料的比较性分析数据Any alternate method or permissible variation that may be employed (e.g.,
alternate starting materials, reactants, solvents, conditions, catalysts,
isolation, and/or purification procedures) should be reported. Comparative
analytical data for the material produced by each variant synthetic method
should be provided.
（3）原料药的纯化Purification of the drug substance
应该详细描述原料的提纯情况和其从最终反应混合物中分离的情况。

其中应该包括以下内容：The description of the purification of the crude new drug substance and its isolation from the final reaction step mixture should be given in detail, and should include:
(1) 原料药的收率范围The yield ranges of the crude product;
(2) 任何用于判断原料产品纯度的检验。

（参见下面第6条）Any tests performed on the crude product to determine its purity (see item 6, below);
(3) 详细的分离和纯化过程的记录（如：对于重结晶过程：所使用的溶媒，与原料产品相关的溶媒的数量，溶媒在热时候是否被过滤，是否使用了脱色剂，冷却温度与和最终温度，母液的使用和再使用，溶媒是否进行了二次回收。

A detailed description of the isolation and purification procedures (e.g., for recrystallization: the solvent used, the quantity of solvent in relation to the amount of crude product, whether it is filtered while hot, whether a decolorizing agent is used, the rate of cooling and the final temperature, the use or re-use of any mother liquors, and if second crops are obtained);
(4) 替代的提纯步骤（参见II.D.2.b.中的最后一段；参见II.G）Alternative purification procedures (see the last paragraph of section II.D.2.b.; see also section II.G.);
(5) 提纯产品的收率范围（重量和百分比）The yield range (weight and percent) of the purified product;
(6) 证明提纯过程增加纯度的有关证据，例如色析法的前后对比Evidence demonstrating that the purification procedure improves the purity, such as before-and-after chromatographic illustrations.
当提纯工艺被验证后，只需提供最初产品批次的检验相关信息。

This testing and information may be necessary only on initial production batches, once the purification process has been verified or validated.
（4）合成的变化Changes in the synthesis
相关合成的变化应该作为DMF的补充来提交。

为改变新药物递交(NDA)中已经批准的有关原料药的合成方法，制剂递交者也需要提交一个批准的补充文件，这包括有关溶媒的改变。

Proposed changes in the synthesis should be submitted to the application as a supplement for an approved NDA or as an amendment to an IND, a DMF, or a pending NDA. An approved supplement is required [21 CFR 314.70(b) (1) (iv)] to change the method of synthesis approved in the NDA for the drug substance, including a change in solvents.
当合成的路线发生改变时（如：反应和中间体与新药递交(NDA)所批准的相关内容不同时），应该提供每一合成路线的比较分析数据（如：完整的纯度档案数据）。

下面我们将讨论有关变化旨在重新定义起始原料的情况。

When the route of synthesis is changed (i.e., reactions and/or intermediates are different from those approved in the NDA), comparative analytical data (i.e., a complete purity profile) for the drug substance made by each route should be provided. A special case, where the proposed change is to redefine the starting material, is discussed below.
当用于原料药最终结晶的溶媒发生变化时，应该检查原料药有关晶形和溶剂化物的变化；参见II.G。

原料药必须符合有关晶形和溶剂化物的原定规格。

When there is a change in the solvent used for the final crystallization of the new drug substance, the new drug substance should
be examined for changes in crystalline form and/or solvation; refer to section II.G. The new drug substance must meet its original specifications for crystalline form and/or solvation.
有关其它的反应和提纯的溶媒改变也需要一份补充递交，补充递交中应该提供该改变可以产生同等质量和纯度的产品（化合物或中间体）的证据，但无需考虑形态学问题。

Solvent changes for other reaction steps or purifications also require a supplemental application. The application should contain evidence that the
change affords material (compound or intermediate) of equivalent quality and
purity, but morphology need not be considered.
如果递交者想缩短新药递交(NDA)中批准的合成方法或者通过重新定义起始原料时，则需要提交一个补充文件(21 CFR 314.70(b) (1))。

该起始原料是一种可从商业渠道获得的用于合成的化合物，该化合物必须是新药递交中（NDA）批准的中间体，而且，必须满足起始材料"b" 和"c"标准要求。

An approved supplement is required (21 CFR 314.70(b) (1)) if an applicant wants to shorten the synthesis approved in the NDA or develop a new synthetic method by redefining the starting material, in order to employ a compound later in the synthesis that has become commercially available. This compound must have been an intermediate in the approved NDA synthesis, and must meet both the "b" and "c" criteria for starting material.
在完成原料药的合成之前，该化合物至少在两个完整的合成阶段前使用。

依据所引用的参考文献（应该提供相关拷贝）的充分性，需要提供起始原料的纯度和特性等额外信息，这包括足够的文献资料（如提供的复印件）。

The compound should be used at least two full steps before the new drug substance if possible (i.e., it should be prior to the final intermediate). Additional information on the characterization and purity profile of the starting material may be needed, depending on the adequacy of the literature references cited (copies should be provided).
对于学术期刊所引用的化合物，详尽的出版材料就够了（如：有关杂质检验的额外信息）。

在有关专利中所规定的化合物，需要提供其完整的特性和纯度档案。

应该描述用于检验每一批新起始原料的分析检测程序。

建立一个通用的检验方案通常就可以了。

For compounds cited in journal articles, an elaboration of the published material (i.e., additional information about testing for impurities) may suffice. For compounds described in patents, both complete characterization and a full purity profile will usually be needed. Analytical test procedures used to qualify each new source/supplier of the new starting material should be described. A general testing protocol may be suitable.
递交者应该通过直接的比较（如：通过分析和使用）证明该化合物与用于临床试验用的新原料药等效，同时应该证明该化合物的符合承诺的标准。

使用至少是试验性规模（如:要大于实验室规模）。

The applicant should demonstrate by direct comparison (i.e., both by analyses and by a use test) that the compound is equivalent to the material used to make the new drug substance employed in the clinical trials, and that the acceptance tests and specifications for the compound are adequate. The use test should be at least on a pilot scale (i.e., larger than bench scale).
应该提供用该材料所生产的前三批产品的完整检验结果。

该检验的广度和深度要和用于检测一个新的参考标准品的相同。

A commitment to submit results from thorough examination of the
first three full-scale batches made with the material should be provided. The examination should be similar in scope and extent to the testing involved in qualifying a new reference standard.
对于依据联邦法典21 CFR 314.70(c) (3)所做的改变类型，只要有对合成过程的充分描述文件，就可以。

这样的改变，无需FDA的事先批准就可以执行。

For changes of the type permitted by 21 CFR 314.70(c) (3), an adequate synthesis description on file would facilitate a conclusion that changes in site of manufacture of the new drug substance do not require prior FDA approval for implementation.
4、参照标准品Reference Standard
原始递交的申报文件应该包括任何所使用的参照标准品的制备过程的描述，包括对提纯步骤的描述，参见II.F.3.The original application should include a full description of the preparation of any reference standard substance used, including the description of the purification steps. See also section II.F.3. II.D.4.
五、生产过程的控制
1、中间体和生产过程的控制Intermediates and In-process Controls
相关法规要求在合成过程中选择一些中间环节实施控制（检测项目与参数要求），以保证合成和提纯工序顺利进行，并保证检测后的中间体适合于以后的加工。

申请者可以根据对整个合成工艺的开发和确认的经验，自行确定对那些中间体或加工环节进行检测及进行那些检测项目。

在早期的开发阶段，每一个步骤通常都进行了检验（至少是对反应的内容），每一个中间体至少都进行与纯度有关参数的测定，包括纯度的估计。

随着合成经验的积累，应选择关键的反应步骤和中间体进行监控。

在递交新药申请(NDA)时，生产过程的控制点应该已经选定，相关控制参数和检验方法也已确立，以满足法律的要求。

The regulations require that controls (specifications and tests) be employed at selected intermediate stages of the synthetic process to assure that the synthetic and purification procedures are operating properly and that the intermediate tested is suitable for subsequent processing. The choice of which intermediate(s) or steps in the process to test, and the kind of testing required, are the responsibility of the applicant based on his experience during the development and verification of the total synthetic process. In early development work, every step would usually have been examined (at least for extent of reaction) and every intermediate at least partially characterized with some estimate of purity. As experience is gained with the synthesis, the critical reaction steps and intermediates to be monitored are selected. At the time of NDA submission, in-process control points should have been selected and appropriate specifications and tests established to meet the requirements of the regulations.
这里描述的整个操作都是合成工艺验证的一个部分。

应当解释选择相关控制点和中间体的根据。

应当证明控制参数和检测方法对合成过程的控制是充分的。

应当依据相关控制点（控制参数和检测方法）来提供控制参数范围的书面描述。

通常，较宽的参数范围需要更严格的控制（参见：II.E.b.（回收和再加工））。

在新药申请(NDA)被批准后，随着经验的积累，可能需要修改生产过程的控制程序。

该控制程序的改变需要额外的验证（参见：IV）。

This whole operation is part of the process validation of the synthesis. The basis for selecting control points
and intermediates should be explained, and the adequacy of the specifications and tests to control the synthetic process demonstrated. The ranges for the operating parameters in the written description of the synthesis should be chosen in light of the controls (specifications and tests). Generally, broad operating ranges will require stricter controls. (See also section II.E.b. (recovery and rework) below.) With additional experience subsequent to NDA approval, the choice and nature of in-process control procedures may require modification. Changes in in-process control procedures will require additional validation (see section IV).
设计控制为得是：Controls may be designed to
(a) 证明已获得了想要生产的产品demonstrate that the desired product has been obtained;
(b) 确定关键的物理特征（如：熔点、旋光度等）determine a key physical property (e.g., melting point, optical rotation, etc.);
(c) 确定中间体的纯度和杂质determine purity/impurity of the intermediate;
(d) 确定收率是限定在通常的操作范围之内determine that the yield is within the normal operating range.
在某些情况下，对中间体的控制是不可行的（如：它们处于溶液状态或直接加工成下一个化合物）。

如有可能，检测也可仅限于对合成过程的监控（如：反应是否完成）。

In some cases no controls for the intermediate may be feasible (e.g., where they are held in solution, or are directly processed to the next compound). When appropriate, testing may consist only of a test designed to monitor the progress of the synthesis (i.e., reaction completion).
上面所列的部分或全部生产过程中的控制在每一个控制点都应该符合控制检测的要求。

关键、核心和最后的中间体（参见：术语表）通常至少应当符合以上所列过程控制的要求。

为减少最终的大规模清除，从第一个中间体到原料药本身,中间体的纯度应该逐渐提高。

Some or all of the above kinds of process controls should be met at each point selected for in-process control testing. Pivotal, key, and final intermediates (see Glossary, and below) would ordinarily require at least the in-process controls listed above. To eliminate the need for heroic final cleanups, it is expected that the degree of purity of intermediates will increase progressively, from the first intermediate on to the drug substance itself.
2、关键中间体（见术语表）Pivotal intermediate(s) (See Glossary.)
应该用足够的细节（如详细描述其特征）描述任何关键中间体，并作为控制参数与检验的一个部分，对其进行严格的检查，其中还包括通过层析法，以避免忽略由替代合成方法产生的杂质。

如此严格的检验无需经常进行，但是当供应商或合成发生改变时，要做以上检查。

当关键中间体接近成为最终中间体时，对其进行的检测程度和纯度要求也应该增加Any pivotal intermediate should be described in adequate detail (i.e., be well characterized) and be subject to rigorous examination procedures as part of the specifications and tests, including thorough chromatographic examination so as to avoid overlooking impurities arising from alternative syntheses. Such rigorous examination need not be routine but may be needed in special circumstances such as when the supplier or synthesis is changed. The degree of testing and the level of purity required for a pivotal intermediate should increase as its position in the synthesis
scheme approaches the final intermediate.
3、核心中间体（参见术语表）Key intermediate(s) (See Glossary.)
对核心中间体，应制定充足的规格，以保证能生产出所需的分子结构和纯度的最终产品。

检测程序应该能够标明，所需要的转换（如：手性的引入或立体定向反应）已经按照预想的方式发生，并在预期的收率范围内，同时通过定量分析表明，不需要的材料（如：异构体、副产品、起始原料）已经限制在既定限度之内。

The specifications should be adequate to assure that the molecular architecture necessary for the final product, as well as the requisite degree of purity, have been attained. Test procedures should thus show that the desired transformation (such as introduction of chirality, or a stereospecific reaction) has occurred in the manner expected and within the normal yield range expected, and show by quantitative determination(s) that undesired materials (e.g., isomers, by-products, starting materials) are within established limits.
4、最终中间体（参见术语表）Final intermediate (see Glossary.)
关于最终中间体的规格和检验应该与原料药的规格和检验同样广泛和严格，因为这是最终反应前的最后监控纯度和杂质的机会。

Specifications and tests for final intermediate should be nearly as extensive and stringent as those for the new drug substance itself, because this is the last opportunity to monitor purity and impurities before the final reaction.
5、返工Reprocessing
对不符合加工规格要求的中间体，可以按照新药申请(NDA)中所描述的提纯方法进行进一步提纯。

当采用替代的提纯方法时，获得的产品应象第一次一样，接受最后加工操作与检验。

Intermediates which do not meet in-process specifications may be further purified using the same purification procedure described in the NDA. When an alternate purification procedure is used, the recovered material should be subjected to the same final processing operation and the same testing as for the first time.
FDA认识到，有时操作条件（如时间和温度）会偏离新药申请(NDA)中的描述。

应当制定一个方案，规定当反应条件或操作控制参数超出通常的范围时（如：偏离或较小的背离），应当采用什么样的程序，来使该批中间体或原料药合格。

该方案应该为确保该批产品合格所使用的额外分析检验。

这样的检验应该比日常要求的控制参数和检验范围更广。

如需要，可以使用非常规分析方法。

例如,对超出正常条件的新原料药批产品（如：反应条件超出一般范围），应该按使用分析标准参照品是否合格的程序来进行检验。

FDA recognizes that operating conditions (such as time and temperature) occasionally deviate from the NDA description. A protocol should be provided for the procedure which will be used to qualify the batch of intermediate or drug substance as meeting specifications when reaction conditions or operating parameters fall outside the typical/normal range (i.e., "excursions," or minor deviations). The protocol should describe the additional analytical testing which will be used in qualification of the batch. The testing should be more extensive than required by routine specifications and tests and may include, as appropriate, the use of nonregulatory analytical methods. For example, batches of new drug substance in this category (i.e, when reaction conditions are outside the norm)。